Journal article · Vestibular← The news desk

✦ The Dispatch

Endolymphatic duct blockage versus intratympanic gentamicin for refractory Ménière's disease

A dispatch from PubMed — filed

The goal of Ménière's disease management is to control vertigo while minimizing adverse effects. Although intratympanic gentamicin(ITG) is effective, its vestibulotoxic and cochleotoxic potential remains a concern. OBJECTIVE: To compare ITG and endolymphatic duct blockage(EDB) in terms of vertigo control, hearing preservation, and vestibular function.

Continue reading at PubMed

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

Results comparing endolymphatic duct blockage to intratympanic gentamicin for refractory Ménière's disease are directly relevant to surgical and medical decision-making; audiologists managing these patients should review the full data to understand hearing and vertigo outcomes for each approach.

✦ Why It Matters ✦

For the significant minority of Ménière's patients who fail medical therapy, head-to-head evidence comparing a surgical option with intratympanic gentamicin is scarce, making this study directly practice-informing.

✦ Key Points ✦
  1. 01Head-to-head comparison of endolymphatic duct blockage (surgery) vs. intratympanic gentamicin (antibiotic injection) in refractory Ménière's disease.
  2. 02Primary focus is vertigo control rate and adverse effects, including potential hearing loss from gentamicin (ototoxicity).
  3. 03Both interventions target patients who have not responded to conventional treatments.
  4. 04Intratympanic gentamicin carries a known risk of ototoxicity (medication-related hearing damage); the study quantifies this risk.
  5. 05Results may help clinicians and patients choose between a surgical and a pharmacological second-line approach.
✦ Claims & Evidence ✦

Endolymphatic duct blockage and intratympanic gentamicin differ in vertigo control rates in refractory Ménière's disease.

studyunclear

Intratympanic gentamicin carries a risk of ototoxicity (hearing damage) as an adverse effect in Ménière's disease treatment.

studysupported
✦ Research metadata ✦
PMID
43013507
DOI
10.1080/00016489.2026.2750761.
Journal
Acta Oto-Laryngologica
Publication type
research_article
Evidence level
2b
Population
Patients with refractory Ménière's disease unresponsive to conventional treatment
Intervention
Endolymphatic duct blockage (surgical procedure)
Comparator
Intratympanic gentamicin injection

Primary outcomes

Vertigo control rate; Adverse effects including ototoxicity

✦ Related stories ✦